Trial
NCT03394196
RESIST-2: 2nd-line ART for HIV-2 Infection
UnknownTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Washington
Collaborators
Clinique des Maladies Infectieuses, CHNU de Fann, Dakar, Senegal; Centre de Sante de Ziguinchor, Casamance, Senegal; Janssen Pharmaceutica; Merck Sharp & Dohme LLC; National Institute of Allergy and Infectious Diseases (NIAID)
Condition
HIV-2 Infection
Intervention
HIV-2 Genotypic Drug Resistance Testing using DBS
Why stopped
COVID-19 and Funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-25